Published in final edited form as:

Eur J Pharmacol. 2011 June 11; 660(1): 88–93. doi:10.1016/j.ejphar.2010.10.109.

Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challenge

Victor J. Hruby, Minying Cai, James Cain, Joel Nyberg, and Dev Trivedi

Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721 U.S.A

Abstract

The major pharmacophore for the melanocortin 1,3,4 and 5 receptors is the sequence -His-Phe-Arg-Trp-. There is a need for potent, biologically stable, receptor selective ligands, both agonists and antagonists, for these receptors. In this report we briefly examine the structural and biophysical approaches we have taken to develop selective agonist and antagonist ligands that can cross (or not) the blood brain barrier. Remaining questions and unmet needs are also discussed.

Index Words

Melanocortin Receptor Ligands SAR; Selective Ligands for MCRs; Melanocortin Receptor Selective Ligands; Orthosteric and Allosteric Ligands; Agonists and Antagonists for MCRs

1. Introduction

Proopiomelanocortin, a primordial animal gene, its processed products, the melanotropin peptides, and their receptors has a long and storied history (e.g. Hadley, 1988; Vaudry and Eberle, eds., 1993). Early work (until the 1990s) concentrated primarily on the functions of adrenal corticotrophic hormone (ACTH) and the adrenal gland, α -melanocyte stimulating hormone (α -MSH) and pigmentation, and β -endorphin and pain. In the 1990s five melanocortin receptors were cloned (Cone, ed. 2000). In addition to the melanocortin receptor 1 (melanocortin MC₁ receptor, pigmentary receptor) and the melanocortin receptor 2 (melanocortin MC₂ receptor, adrenal receptor), three other receptors were discovered, and their expression in the periphery and in the central nervous system suggested that numerous possible biological activities might be associated with the POMC ligands and these receptors including, in addition to pigmentary effects and the production of glucocorticoids in response to stress: effects associated with feeding behaviors (obesity, anorexia), sexual behavior (erectile dysfunction, sexual motivation), temperature control, pain, inflammatory response, immune response, and many others (e.g. Cone, 2000). A vexing problem is the observation that the primary native ligand for the melanocortin MC₁ receptor, melanocortin MC₃ receptor, melanocortin MC₄ receptor and melanocortin MC₅ receptor is α -melanocyte stimulating hormone (α -MSH) or possibly γ -melanocyte stimulating hormone (γ -MSH). These native ligands are rather none-selective for these 4 receptors, and the basic pharmacophore is the sequence -His-Phe-Arg-Trp- (Hruby et al., 1987) which is found in both α -MSH and γ -MSH (Figure 1). α -MSH and other native melanotropin peptides are biologically unstable, being easily hydrolyzed by proteases, and in addition the Met residue

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

in α -MSH is easily oxidized which leads to a modified ligand with decreased biological activity. Thus a primary need in this field is to obtain melanotropin analogues which are: 1) biologically stable to proteolysis and oxidation; 2) agonists or antagonists; 3) selective for one of the melanocortin receptors; 4) able to cross the blood-brain-barrier (or not); and 5) orthosteric or allosteric ligands. Development of such ligands has been critical not only to establish structure-activity relationships but equally importantly, to establish the biological functions of the various melanocortin receptors and melanocortin systems. In this paper, we will briefly discuss the fundamental approach we have developed toward these objectives which requires a highly interdisciplinary program involving asymmetric synthesis, peptide and peptidomimetic synthesis, computational chemistry, biophysics and conformational determination, molecular pharmacology, molecular biology and close collaboration with biologists (e.g. Hruby, 1982; Hruby et al., 1990; Hruby et al., 1997; Hruby et al., 2001; Hruby, 2002; Hruby, 2009).

2. Materials and Methods

2.1 Asymmetric Synthesis

It often is necessary to synthesize novel amino acids in order to examine the conformational or topographical properties of a peptide or peptidomimetic. This important topic will not be discussed here except to say we have concentrated on chi-constrained aromatic amino acids (for reviews see Hruby et al. 1990, 1997; Hruby and Qian, 1994) and constrained structures of proline (e.g. Hruby, 2009) primarily as a way to examine the importance of chi space in SAR studies.

2.2 Peptide and Peptidomimetic Synthesis

Most of the peptide and peptidomimetic syntheses have been done using either the N^{α} -Boc or the N^{α} -Fmoc strategies of peptide synthesis (Hruby et al., 1992; Hruby and Meyer, 1998). Though the native melanotropin peptides are all linear compounds, we and others have made many cyclic analogues since our initial synthesis of c[Cys⁴, Cys¹⁰]- α -MSH (Sawyer et al., 1982). For each of these cases whether disulfides, sulfides, lactams, or others, appropriate synthetic conditions needed to be developed for the particular cyclic template. In some cases cyclization could be done on the solid support, whereas in others it needed to be done in solution, often assisted by microwave conditions. In general, orthogonal protection of the functional group(s) to be cyclized is required. Details are found in the individual publications which first established the use of various cyclic templates.

2.3 Peptide and Peptidomimetic Purification and Analysis

Most purifications of our peptides and peptidomimetics are done by high performance liquid chromatography (HPLC) which, in its analytical format, also serves to evaluate purity. We usually do thin layer chromatography (TLC) with 2 or 3 different solvent systems. Also of great use are gel filtration for final purification, and ion exchange chromatography.

2.4 Conformational Analysis, Computational Chemistry and Modeling

Thus far, X-ray crystal structures of the melanocortin receptors have not been obtained, and in general it has been very difficult to obtain X-ray crystal structures of membrane proteins especially G-protein coupled receptors (GPCRs) such as the melanocortin receptors. Furthermore, none of the native melanotropin peptides have had their X-ray structures determined. Thus obtaining conformational and topographical information about the melanotropin ligands via computer assisted modeling and computational chemistry in conjunction with biophysical studies has played a crucial role in the development of three dimensional structure activity relationships (SARs) from the earliest days of our studies in

this area in the early 1980s (e.g. Sawyer et al., 1980, 1982). This approach includes 2-dimensional NMR studies in conjunction with computational chemistry. Though details will not be discussed, they can be found in the papers which involve the development of our new, mostly cyclic templates.

2.5 Biological Activity Assays. Receptor Binding Assays

Competition binding assays and functional assays are carried out using HEK293 cells stably expressing the melanocortin MC₁receptor, melanocortin MC₃receptor, melanocortin MC₄ receptor and melanocortin MC₅ receptor as described previously (Cai et al., 2005a; Cai et al., 2005b; Cai et al., 2004a) using [¹²⁵I]-[Nle⁴,D-Phe⁷]- α -MSH (Perkin Elmer Life Science) as the radioligand and [Nle⁴,D-Phe⁷]- α -MSH (NDP- α -MSH) and Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂(MT-II) as the standard control ligands.

2.6 Data Analysis

IC₅₀ and EC₅₀ values generally represent the mean of 2 experiments run in triplicate. The values and their associated standard errors are determined by fitting the data using nonlinear least square analysis via GraphPad Prism 4 (GraphPad Software, San Diego, CA).

3. Results and Discussion

In our early work the major goals were to obtain α -MSH analogues (agonists and antagonists) which would be more biostable than the native ligand α -MSH. Our initial modifications were to introduce the pseudoisosteric amino acid norleucine (Nle) into position 4 in place of methionine to prevent oxidation of Met⁴ to its sulfoxide or sulfone, and to replace Phe⁷ with D-Phe⁷ to enhance stability against proteolytic enzymes. The resulting peptide [Nle⁴, D-Phe⁷]- α -MSH (Sawyer et al., 1980, NDP- α -MSH, MT-I) (Figure 1) was found to be more potent than α -MSH and it was significantly more stable *in vivo* (Figure 2). In addition, it was found to have highly prolonged biological activities in a variety of species. This molecule has been used by many investigators for studies of biological functions of melanocortin receptors since it has high potency at the melanocortin MC₁ receptor, melanocortin MC₃ receptor, melanocortin MC₄ receptor and melanocortin MC₅ receptor and good *in vivo* stability and biodistribution. Computational studies and molecular modeling suggested it had a β -turn structure centered at the D-Phe⁷ residue, and to test this hypothesis we designed and synthesized the cyclic analogue c[Cys⁴Cys¹⁰]- α -MSH (Ac-Ser-Tyr-Ser-c[Cys⁴-Glu-His-Phe-Arg-Trp-Cys¹⁰]-Lys-Pro-Val-NH₂) (Sawyer et al., 1982) which also was found to be a super potent analogue, though not with prolonged activity. Extensive SAR studies eventually led to the conclusion that the tetrapeptide sequence -His-Phe-Arg-Trp- was the principal pharmacophore for α -MSH bioactivity (Hruby et al., 1987) though smaller fragments especially with a D-Phe still could have potent bioactivity (e.g. Sawyer et al., 1993). Truncation studies, conformational studies, and molecular modeling and computational studies led to the design of the truncated cyclic lactam analogue of α -MSH, Ac-Nle-c[Asp⁵, D-Phe⁷, Lys¹⁰]- α -MSH-(4-10)-NH₂ (Al-Obeidi et al., 1989a, 1989b; MT-II). This analogue (Figure 2) was highly potent in several assays and was found to be very stable *in vivo* and to cross the blood brain barrier (BBB). NMR based conformational analysis, in conjunction with computational chemistry provided evidence to support the β -turn conformation of this cyclic analogue of α -MSH (Ying et al., 2003). This compound also has been widely used for a very wide variety of biological activity studies by many investigators. We have used Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ (MT-II) and the linear analogue [Nle⁴,D-Phe⁷]- α -MSH (MT-I) (Table 2) for human clinical trials for pigmentation effects in humans (Hadley et al., 1993; Dorr et al., 1996) and for psychogenic erectile dysfunction in men (Wessells et. al.,1998).

3.1 Recent Orthosteric Selective Ligands

In our efforts to obtain selective ligands for the melanocortin receptors, we have examined a wide variety of scaffolds to test the basic hypothesis that selectivity could arise from two sources: 1) conformational and/or topographical (chi space) differences in the arrangements of pharmacophore elements; and/or 2) differences in receptor address moieties in the structure. In this paper we will illustrate examples of testing this strategy, but due to space limitation will not discuss the biophysical studies, computational chemistry and computer assisted modeling that went into these considerations.

The first example H-Tyr-Val-Nle-Gly-His-D-Nal(2')-Arg-Trp-Asp-Arg-Phe-Gly-NH₂, (Table 1, 1) was made some time ago (Balse-Srinivasan et al., 2003a). This linear γ -melanocyte stimulating hormone analogue has, to our knowledge, a unique biological activity profile at the melanocortin MC₃ receptor, melanocortin MC₄ receptor and melanocortin MC₅ receptor. It is a potent agonist at the human melanocortin MC₄ receptor, but an antagonist at the human melanocortin MC₃ receptor and human melanocortin MC₅ receptor. It would be interesting to evaluate its *in vivo* biological activities in feeding behavior, erectile function and cardiovascular function. The cyclic analogue **2** (Table 1) has a unique biological activity profile being a potent and selective antagonist ligand at the human melanocortin MC₁ receptor with weak agonist activity at the human melanocortin MC₃ receptor and the human melanocortin MC₅ receptor, and no binding or functional activity at the human melanocortin MC₄ receptor. We currently are preparing a paper on its structure activity relationship. In the meantime, B. Kest and colleagues (Juni et al., 2010) have shown that this ligand can modulate hyperalgesia in a gender specific manner. An analogue of Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ in which the Nle⁴ residue is replaced by a D-Phe and the His⁶ residue by a Pro residue (**3**, Table 1) (Grieco et al., 2006) gave a ligand that was more selective as a human melanocortin MC₃ receptor agonist than [D-Trp⁸] γ -melanocyte stimulating hormone (Grieco et al., 2000) since it had antagonist activities at both the human melanocortin MC₄ receptor and human melanocortin MC₅ receptor. A very interesting and unique conformationally and topographically constrained analogue **4** (Table 1) was examined for its biological activity profile. Aba is a cyclic aromatic amino acid mimetic 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one. It has a unique conformation, particularly of the aromatic side chain groups relative to Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ (MT-II), which likely accounts for its unique biological activity profile with highly selective antagonist activity at the human melanocortin MC₃ receptor (Ballet et al., 2007). Another interesting human melanocortin MC₃ receptor antagonist is the ligand **5** (Table 1) which is a cyclic disulfide-containing ligand with constrained cystine amino acid penicillamine (β , β -dimethylcystine) in the 4 position and the C-terminal sequence of β -melanocyte stimulating hormone (β -MSH) (Balse-Srinivasan, 2003b). This compound has highly potent and selective melanocortin MC₃ receptor antagonist activity.

3.2 Alternative Template Designs

Based on the conformation properties of Ac-Nle⁴-Ac-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ (MT-II) and Ac-Nle⁴-c[Asp⁵,D-Nal(2')⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ (SHU9119) (Ying et al., 2003) we have utilized computer assisted modeling and computation chemistry to design a number of other novel scaffolds, and will discuss a few recent examples here. The first examples involves substitution of the Arg⁸ residue in MT-II with a 3R-thiol-Arg residue or a Cys residue with N ^{α} -guanidinybutyl group at the terminal Trp-NH₂ residue (**6** and **7**, Table 2) (Ying et al., 2006). This novel design also gave novel biological activity results. As can be seen in Table 2, both **6** and **7** had no binding or functional activity up to 10⁻⁵M at the human melanocortin MC₁ receptor, human melanocortin MC₃ receptor, or human melanocortin MC₅ receptor. At the melanocortin MC₄ receptor both **6** and **7** showed potent

binding affinity, but no or minimal adenylate cyclase activity. Interesting however, the ligands only could displace 50% of the radioactive ligand [125 I]-NDP- α -MSH in competitive binding experiments, indicating that they are potent allosteric antagonists of the human melanocortin MC₄ receptor. Furthermore, when the D-Phe⁷ residue was replaced with a D-Nal(2') residue, the peptidomimetic ligand no longer binds to the human melanocortin MC₄ receptor (data not shown, Ying et al., 2006), but now binds only to the human melanocortin MC₅ receptor, though weakly (IC₅₀=210 nM).

Based on computer assisted molecular modeling and computational chemistry, we also have designed a non-peptide, but amino acid based, scaffold to examine structure activity relationships (Cain et al., 2006). The bicyclic scaffold (**8** and **9**, Table 2) is derived from proline and its analogues and α -amino acids, and readily lends itself to asymmetric substitution at several positions in the bicyclic scaffold. The diastereoisomers **8** and **9** have quite different biological activity profiles, with the peptide mimetic **8** binding only to the human melanocortin MC₅ receptor as an allosteric antagonist. On the other hand, compound **9** binds in the nanomolar range as an allosteric antagonist at both the human melanocortin MC₁ receptor and human melanocortin MC₃ receptor. Further studies of related analogues are in progress.

3.3 N-Methylated Analogues of MT-II

Though backbone N-methylation has been used in structure activity relationship studies of backbone biologically active peptides for many years, a systematic examination of the effects of N-methyl modifications of peptides generally has not been examined due to the difficulties in the synthesis of multiple N-methylated peptides. Recently, however Kessler and co-workers have worked out a general synthetic approach for "in situ" N-methylation during solid phase peptide synthesis that greatly facilitates synthesis of multiple N-methylated peptides (e.g. Biron and Kessler, 2006). We have collaborated with Kessler and coworkers to systematically N-methylate the amide bonds in the cyclic structures MT-II and SHU-9119 (Figure 2) (Doedens et al., 2010). The N-tetramethyl substituted analogue **10** (Table 1) is a potent and selective agonist for human melanocortin MC₁ receptors with very weak antagonist activities at the human melanocortin MC₃ receptor and no binding activity at the human melanocortin MC₄ receptor and human melanocortin MC₅ receptor. NMR-based conformation analysis demonstrated that the more constrained conformation of **10** compared to Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ (MT-II) provides interesting insights into its selectivity for the human melanocortin MC₁ receptor. In this regard it is interesting to note that the corresponding trimethylated analogue's potency decreases 4 fold at the human melanocortin MC₁ receptor, but now the analogue does not bind to the human melanocortin MC₃ receptor (Doedens et al., 2010) (data not shown).

3.4 Melanocortin Peptides vs. Small Molecule Ligands for Melanocortin Receptors

It has become increasingly clear in the past few decades that G-protein coupled receptors such as the melanocortin receptor can choose more than one signaling pathway of intracellular communication depending upon the ligand. The vast majority of hormones and neurotransmitters are peptides (or proteins), but scientists often seek to develop non-peptide mimetics of the peptide or protein ligands. A question that arises is whether non-peptide ligands that are presumed to be mimetics, actually signal via the same mechanism. We have examined this question by comparing (Cai et al., 2004) the signaling mechanism of Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ (MT-II), a potent human melanocortin MC₄ receptor agonist (vide supra) and N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (THIQ) a non-peptide agonist selective for the human melanocortin MC₄ receptor. For this purpose we have examined

phosphorylation in the human melanocortin MC₄receptor following treatment with the two agonists. We also have examined C-terminal and third loop mutagenesis, and its effect on Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂(MT-II) and THIQ binding. We have used confocal and two photon laser scanning fluorescence microscopy to examine the ligand dynamics in live cells possessing the human melanocortin MC₄receptor. In results to date, we have shown that third loop mutations do not effect Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂(MT-II) binding and only slightly affect cyclic adenosine monophosphate (cAMP) formation, whereas for N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (THIQ) there is some change in binding affinity and a more significant change in cAMP formation. In the C-terminal modifications, Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂(MT-II)treatment leads to green fluorescent protein- β -arrestin aggregation and internalization, whereas THIQ treatment causes no GFP- β -arrestin aggregation but nonetheless internalization occurs. Furthermore, Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]- α -MSH(4-10)-NH₂ leads primarily to phosphorylation at the C-terminal of the human melanocortin MC₄ receptor, whereas THIQ treatment leads primarily to phosphorylation at the third and second intracellular loops. These results suggest that non-peptide and peptide agonist ligands for the human melanocortin MC₄receptor have different signaling mechanisms. The significance of these differences for medical applications and for potential biological outcomes is unclear, but deserves further investigation.

3.5 Conclusions and Unsolved Questions

Using novel scaffolds and conformational constraints, it is slowly becoming possible to obtain potent (<10 nM IC₅₀s and EC₅₀s) and receptor selective (>200 fold) agonist and antagonist analogues for the human melanocortin MC₁ receptor, human melanocortin MC₃receptor, human melanocortin MC₄receptor, and human melanocortin MC₅receptor. However, we still are not at the point where we know precisely the structural and conformation features that can reliably predict structure activity relationship differences for ligands for the melanocortin receptors. Clearly, we will have to continue with systematic, careful, 3-dimensional studies of carefully designed ligands with substantial differences in affinity and efficacy (>1000 fold) for these melanocortin receptors to have some certainty regarding the differential 3-dimensional structural pharmacophore for both agonists and antagonists (each will be different for each receptor) at the melanocortin MC₁receptor, melanocortin MC₃receptor, melanocortin MC₄ receptor, and melanocortin MC₅receptor. In addition, there are a number of other outstanding unresolved issues to be addressed. In particular, when medical applications are sought, are the agonist, antagonist, cellular and animal screens we are using sufficiently discriminating? How are the central and peripheral actions of the melanocortin receptor different, are there integrated feedback loops and so forth? How are orthosteric vs. allosteric ligands different in desired bioactivities and undesirable bioactivities? How can feeding behavior, sexual behavior, cardiovascular effects, and related functions be separated in a single ligand? Are modulation of pain, immune response, and other outstanding unresolved issues being adequately addressed? Are modulation of pain, immune response, and other 'bioactivities' of melanotropic peptides completely related to melanocortin receptors or are they also dependent on participation of other receptor systems? These and many other questions still remain. Our understanding of how the melanocortin receptors and their ligands are integrated into so many critical biological functions should keep us modest in what we know, but excited about the many opportunities we have to make a major impact in understanding human health and disease.

Acknowledgments

I am particularly grateful to the many outstanding collaborators and colleagues who have made this research possible. Their names appear in the publications referenced here and in many other critical publications. The

research was supported in part by grants from the U.S. Public Health Service. We thank Margie Colie for her help with the manuscript.

References

- Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. Design of a new class of superpotent cyclic α -melanotropins based on quenched dynamic simulations. *J Amer Chem Soc.* 1989a; 111:3413–3416.
- Al-Obeidi F, de Lauro Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of α -melanotropin: design based on molecular dynamics. *J Med Chem.* 1989b; 32:2555–2561. [PubMed: 2555512]
- Ballet S, Mayorov AV, Cai M, Tymecka D, Chandler KB, Palmer ES, Van Rompaey K, Misicka A, Tourwe D, Hruby VJ. Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (aba) scaffold. *Bioorg Med Chem Letters.* 2007; 17:2492–2498.
- Balse-Srinivasan PM, Grieco P, Cai M, Trivedi D, Hruby VJ. Structure-activity relationships of γ -MSH analogues at the human melanocortin MC3, MC4, and MC5 receptors: discovery of highly selective hMC3R, hMC4R and hMC5R analogues. *J Med Chem.* 2003a; 46:4965–4973. [PubMed: 14584947]
- Balse-Srinivasan PM, Grieco P, Cai M, Trivedi D, Hruby VJ. Structure-activity relationships of novel cyclic α -MSH/ β -MSH hybrid analogues that lead to potent and selective ligands for the human MC3R and human MC5R. *J Med Chem.* 2003b; 46:3728–3733. [PubMed: 12904077]
- Biron E, Kessler H. Convenient synthesis of N-methylamino acids compatible with solid-phase peptide synthesis. *J Org Chem.* 2005; 70:5183–5189. [PubMed: 15960522]
- Cai M, Cai C, Mayorov AV, Xiong C, Cabello CM, Soloshonok VA, Swift JR, Trivedi D, Hruby VJ. Biological and conformational study of β -substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity. *J Peptide Res.* 2004a; 63:116–131. [PubMed: 15009533]
- Cai M, Stankova M, Pond SJK, Mayorov AV, Perry JW, Yamamura HI, Trivedi D, Hruby VJ. Real time differentiation of G-protein coupled receptor (GPCR) agonist and antagonist by two photon fluorescence laser microscopy. *J Am Chem Soc.* 2004b; 126:7160–7161. [PubMed: 15186137]
- Cai M, Mayorov AV, Cabello C, Stankova M, Trivedi D, Hruby VJ. Novel 3D pharmacophore of α -MSH/ γ -MSH hybrids leads to selective human MC1R and MC3R analogues. *J Med Chem.* 2005a; 48:1839–1848. [PubMed: 15771429]
- Cai M, Mayorov AV, Ying J, Stankova M, Trivedi D, Cabello C, Hruby VJ. Design of novel melanotropin agonists and antagonists with high potency and selectivity for human melanocortin receptors. *Peptides.* 2005b; 26:1481–1485. [PubMed: 15876475]
- Cain JP, Mayorov AV, Cai M, Wang H, Tan B, Chandler K, Lee YS, Petrov RR, Trivedi D, Hruby VJ. Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors. *Bioorg Med Chem Letts.* 2006; 16:5462–5467. [PubMed: 16931008]
- Cone, RD., editor. *The Melanocortin Receptors.* Human Press; Totowa, NJ: 2000. p. 1-551.
- Doedens L, Opperer F, Cai M, Beck JG, Dedek M, Palmer E, Hruby VJ, Kessler H. Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: Pharmacology and conformational studies. *J Am Chem Soc.* 2010; 132:8115–8128. [PubMed: 20496895]
- Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan ii, a superpotent cyclic melanotropic peptide in a pilot phase-1 clinical study. *Life Sciences.* 1996; 58:1777–1784. [PubMed: 8637402]
- Grieco P, Balse PM, Weinberg D, MacNeil T, Hruby VJ. D-amino acid scan of γ -melanocyte-stimulating hormone: importance of Trp8 on human MC3 receptor selectivity. *J Med Chem.* 2000; 43:4998–5002. [PubMed: 11150170]
- Grieco P, Cai M, Mayorov AV, Trivedi D, Hruby VJ. Structure-activity studies of new melanocortin peptides containing an aromatic amino acid at the N-terminal position. *Peptides.* 2006; 27:472–481. [PubMed: 16303211]
- Hadley, ME. *The Melanotropic Peptides.* Vol. I, II, & III. CRC Press, Inc; Boca Raton, FL: 1988.

- Hadley ME, Hruby VJ, Sharma SD, Dorr RT, Levine N. Melanotropic peptides for therapeutic and cosmetic tanning of human skin. *Ann New York Acad Sci.* 1993; 680:424–439. [PubMed: 8390162]
- Hruby VJ. Conformational restrictions of biologically active peptides via amino acid side chain groups. *Life Sciences.* 1982; 31:189–199. [PubMed: 6126794]
- Hruby VJ, Wilkes BC, Hadley ME, Al-Obeidi F, Sawyer TK, Staples DJ, de Vaux AE, Dym O, Castrucci A-M, de Lauro Hintz MF, Riehm JR, Rao RR. α -Melanotropin: the minimum active sequence in the frog skin bioassay. *J Med Chem.* 1987; 30:2126–2130. [PubMed: 2822931]
- Hruby VJ, Al-Obeidi F, Kazmierski WM. Emerging approaches in the molecular design of receptor selective peptide ligands: conformational, topographical and dynamic considerations. *Biochemical J.* 1990; 268:249–262.
- Hruby, VJ.; Sharma, SD.; Collins, N.; Matsunaga, TO.; Russell, KC.; EdGrant, GA. *Synthetic Peptides: A User's Guide.* W. H. Freeman and Company; New York: 1992. Applications of synthetic peptides to biological and medical research; p. 259-345.
- Hruby, VJ.; Qian, X.; Pennington, MW.; Dunn, BM., editors. *Peptide Synthesis and Purification Protocols.* Vol. 35. Humana Press, Inc; Clifton, NJ: 1994. Approaches to the asymmetric synthesis of unusual amino acids methods in molecular biology; p. 249-286.
- Hruby VJ, Li G, Haskell-Luevano C, Shenderovich MD. Design of peptides, proteins, and peptidomimetics in chi space. *Biopolymers (Peptide Science).* 1997; 43:219–266. [PubMed: 9277134]
- Hruby, VJ.; Meyer, J-P.; Hecht, SM. *Peptides and Proteins.* Oxford Ed; University Press, NY: 1998. Chemical synthesis of peptides *Bioorganic Chemistry*; p. 27-64.
- Hruby VJ. Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind-body problem. *Acc Chem Res.* 2001; 34:389–397. [PubMed: 11352717]
- Hruby VJ. Designing peptide receptor agonists and antagonists. *Nature Reviews Drug Discovery.* 2002; 1:847–858.
- Hruby VJ. Organic chemistry and biology: chemical biology through the eyes of collaboration. *J Org Chem.* 2009; 74:9245–9264. [PubMed: 20000552]
- Juni A, Cai M, Stankova M, Waxman AR, Arout C, Klein G, Dahan A, Hruby VJ, Mogil JS, Kest B. Sex-Specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor. *Anesthesiology.* 2010; 112:181–188. [PubMed: 19996949]
- Mutulis F, Yahorava S, Mutule I, Yahorau A, Liepinsh E, Kopantshuk S, Veiksina S, Tars K, Belyakov S, Mishnev A, Rinken A, Wikberg JE. New substituted piperazines as ligands for melanocortin receptors. correlation to the X-ray structure of “THIQ”. *J Med Chem.* 2004; 47:4613–4626. [PubMed: 15317471]
- Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. [Nle4, D-Phe7]- α -Melanocyte stimulating hormone: a highly potent α -melanotropin with ultralong biological activity. *Proc Natl Acad Sci USA.* 1980; 77:5754–5758. [PubMed: 6777774]
- Sawyer TK, Hruby VJ, Darman PS, Hadley ME. [4-Half-Cystine, 10-Half-Cystine]- α -melanocyte stimulating hormone: a cyclic α -melanotropin exhibiting superagonist biological activity. *Proc Natl Acad Sci USA.* 1982; 79:1751–1755. [PubMed: 6281785]
- Sawyer TK, de Lauro Castrucci AM, Marwan M, Staples DJ, Affholter JA, DeVaux AE, Hruby VJ, Hadley ME. Structure-activity relationships of [Nle4,D-Phe7] α -MSH: discovery of a tripeptidyl agonist exhibiting sustained bioactivity. *Ann N Y Acad Sci.* 1993; 680:597–599. [PubMed: 8390200]
- Vaudry, H.; Eberle, AN., editors. *Ann NY Acad Sci.* Vol. 680. 1993. The Melanotropic Peptides; p. 687
- Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. *J Urology.* 1998; 160:389–393.
- Ying J, Kövér KE, Gu X, Han G, Trivedi DB, Kavarana MJ, Hruby VJ. Solution structures of cyclic melanocortin agonists and antagonists by NMR. *Biopolymers (Peptide Science).* 2003; 71:696–716. [PubMed: 14991679]

Ying J, Gu X, Cai M, Dedek M, Vagner J, Trivedi D, Hruby VJ. Design, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues highly selective for the human melanocortin-4 receptor. *J Med Chem.* 2006; 49:6888–6896. [PubMed: 17154518]

α -MSH Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂

γ -MSH H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-OH

[Nle⁴, D-Phe⁷] α -MSH Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂

Figure 1.

Structure of Some Key Melanotropin Peptides and Peptidomimetics.

α -MSH: Ac-Ser-Tyr-Ser-Met-Glu-*His-Phe-Arg-Trp*-Gly-Lys-Pro-Val-NH₂
 MT-I: Ac-Ser-Tyr-Ser-Nle-Glu-*His-D-Phe-Arg-Trp*-Gly-Lys-Pro-Val-NH₂
 (NDP- α -MSH)
 MT-II: Ac-Nle-c[Asp-*His-D-Phe-Arg-Trp*-Lys]-NH₂
 SHU-9119: Ac-Nle-c[Asp-*His-D-Nal(2')*-Arg-Trp-Lys]-NH₂

α -MSH – Biologically Unstable; T_{1/2} - minutes
 MT-I – Biologically More Stable; T_{1/2} = 2 - 4 hours; Does Not Cross BBB. Non-Selective.
 MT-II – Biologically Stable; T_{1/2} = 1 - 2 days; Crosses BBB. Non-Selective.
 SHU9119 – Antagonist – MC3R and MC4R; Agonist – MC1R and MC5R. Biologically Stable.

Figure 2.
 α -MSH and Its Analogues Developed in Hruby Lab.

Table 1

Selective Orthosteric Ligands for Melanocortin Receptors.

Compound	Binding Affinities 1 IC ₅₀ (nM) ^a					Functional Assays cAMP EC ₅₀ (nM) ^b				
	MC1R	MC3R	MC4R	MC5R	MC1R	MC3R	MC4R	MC5R	MC3R	MC5R
1. Tyr-Val-Nle-Gly-His-D-Nal(2')-Arg-Trp-Arg-Phe-Gly-NH ₂	-	0.84	2.5	1.0	-	>10,000	24(100)	>10,000		
2. c[(CH ₂) ₃ CO-Gly-His-D-Phe-Arg-D-Trp-Cys(S)]-Asp-Arg-Phe-Gly-NH ₂	17	3,900	NB	1,300	NA	100	NA	1300		
3. D-Phe-c[Asp-Pro-D-Phe-Arg-Trp-Lys]-NH ₂	-	3.7	700	1,100	-	4.9	>10,000	>1,000		
4. Ac-Nle-c[Asp-Aba-D-Phe-Arg-Trp-Lys]-NH ₂	NB	50	NB	2,900	NA	NA	NA	NA		
5. Ac-Nle-c[Pen-Glu-His-D-Nal(2')-Arg-Trp-Cys]-Pro-Lys-Asp-NH ₂	-	3.0	750	94	-	NA	NA	NA		
10. Ac-Nle-c[Asp-N-MeHis-D-Phe-N-MeArg-N-MeTrp-N-MeLys]-NH ₂	14	2,200	NB	NB	13	NA	NA	NA		

^aCompetitive binding of ligands vs [¹²⁵I]-NDP- α -MSH;

^bAdenylate cyclase assay; NB – No binding at 10⁻⁵M ligand; NA – No activity at 10⁻⁵M ligand

Table 2

Allosteric Ligands for Melanocortin Receptors.

Compound	^a Binding Affinities a IC ₅₀ (nM)					^b Functional Assays cAMP EC ₅₀ (nM)				
	MC1R	MC3R	MC4R	MC5R		MC1R	MC3R	MC4R	MC5R	
6. Ac-c[Cys-His-D-Phe-N ^ε -Gubu-Cys]-Trp-NH ₂ ^c	NB	NB	1.8 (50)	NB		NA	NA	NA	NA	
7. Ac-c[Cys-His-D-Phe-Cys]-N ^ε -Gubu-D-Trp-NH ₂ ^c	NB	NB	0.7 (50)	NB		NA	NA	>1,000	NA	
8.	NB	NB	NB	0.8 (50)		NA	NA	NA	NA	
9.	40 (50)	40 (50)	NB	NB		NA	NA	NA	NA	

^a Competitive binding of ligands vs [¹²⁵I]-NDP-α-MSH;

^b Adenylate Cyclase Assay; Gubu = Guanidinybutyl; NB= No binding at 10⁻⁵M; NA= No cAMP up to 10⁻⁵M ligand; In=Indole